I. The rationale for extended-release pharmaceuticals II. Terminology III. Extended-release oral dosage forms IV. Delayed-release oral dosage forms V. USP requirements and FDA Guidance for modified-release dosage forms VI. Clinical considerations in the use of oral modified-release dosage form VII. Packaging and storing modified-release tablets and capsules
N-methylcarbamate insecticide residues, including carbamate metabolites, are extracted with methanol. The extract is cleaned up by partitioning and column chromatography on a charcoal/Celite column. Residues are selectively determined
1 Codes: C: complete (>80%); P: partial (50-80%); S: small (<50%); V: variable (approximate percentage when known); R: recovered but no quantitative information available; NR: not recovered
Use of any multiresidue method (MRM) is supported by available information about how potential residues behave through the steps of the method. To provide that support for PAM I MRMs, additional chemicals are continually tested through the method steps and the resulting data compiled in a single database. All PAM
Multiresidue methodology by definition requires determinative steps capable of separating analytes from one another so each can be detected and measured individually. Both gas-liquid chromatography (GLC) and high performance liquid
In recent years, high performance liquid chromatography (HPLC) has grown in popularity as a determinative step for residue analysis, until today it is accepted as complementary to the more traditional gas liquid